Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Evaluation of Neurologic and Psychiatric Adverse Events of Rilpivirine, Elvitegravir, or Dolutegravir in a Real Life Setting

NCT02882230 is registered in ClinicalTrials.gov with Fondation Ophtalmologique Adolphe de Rothschild as lead sponsor.

NCT NCT02882230
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02882230 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Evaluation of Neurologic and Psychiatric Adverse Events of Rilpivirine, Elvitegravir, or Dolutegravir in a Real Life Setting
Lead sponsor
Fondation Ophtalmologique Adolphe de Rothschild
Phase
Observational
Overall status
Terminated
Start date
November 19, 2018
Completion date
January 15, 2019
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv